Chemoprevention of rat prostate carcinogenesis by soy isoflavones and by Bowman-Birk inhibitor.

Chemoprevention of rat prostate carcinogenesis by soy isoflavones and by Bowman-Birk inhibitor. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Chemoprevention of rat prostate carcinogenesis by soy isoflavones and by Bowman-Birk inhibitor. Abstract Text:

David L McCormick,William D Johnson,Maarten C Bosland,Ronald A Lubet,Vernon E Steele,

Epidemiology studies suggest that soy consumption confers protection against human prostate cancer. To identify the soy component(s) that may be responsible for this chemopreventive activity, studies were conducted to determine the influence of a soy isoflavone mixture (PTI G-2535; 45% genistein, 22% daidzein, 2% glycitein) and a soy-derived protease inhibitor (Bowman-Birk Inhibitor Concentrate; BBIC) on prostate carcinogenesis in rats. Prostate cancers were induced in male Wistar-Unilever rats by a sequential regimen of cyproterone acetate and testosterone propionate, followed by a single intravenous injection of N-methyl-N-nitrosourea (MNU) and chronic androgen stimulation. In separate studies, PTI G-2535 and BBIC were administered continuously at 0 (control), 200, or 2000 mg/kg diet, beginning 1 wk post-MNU. PTI G-2535 and BBIC both conferred modest, but statistically significant and dose-related protection against carcinogenesis in the dorsolateral+anterior prostate. These data demonstrate that both the isoflavone and protein (protease inhibitor) components of soy can inhibit prostate carcinogenesis in the rat. However, the modest individual activities of soy isoflavones and BBIC suggest that while both components may contribute to the chemopreventive activity of soy, combination administration (or exposure to whole soy) may be more effective in prostate cancer prevention than is administration of either component alone.

Chemoprevention of rat prostate carcinogenesis by soy isoflavones and by Bowman-Birk inhibitor. Publishing Authors By Initials

DL McCormick,WD Johnson,MC Bosland,RA Lubet,VE Steele,

For similar proteins: plant proteins: soybean proteins: trypsin inhibitor, bowman-birk soybean research abstracts see: proteins: plant proteins: soybean proteins: trypsin inhibitor, bowman-birk soybean research

PUBMED ID PMID:

MEDLINE DATE:

Chemoprevention of rat prostate carcinogenesis by soy isoflavones and by Bowman-Birk inhibitor. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Nutrition and cancer

VOLUME: 57

Page Numbers: 184-93

Journal Abbreviation:

ISSN: 0163-5581

DAY: 3

MONTH: 12

YEAR: 2007

Chemoprevention of rat prostate carcinogenesis by soy isoflavones and by Bowman-Birk inhibitor. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7905040

Chemoprevention of rat prostate carcinogenesis by soy isoflavones and by Bowman-Birk inhibitor. Keywords Mesh Terms:

KEYWORDS: Trypsin Inhibitor, Bowman-Birk Soybean

MESH TERMS: pharmacology

Chemical & Substance for Abstract: Chemoprevention of rat prostate carcinogenesis by soy isoflavones and by Bowman-Birk inhibitor. Information

Substance Name: Methylnitrosourea

Registry Number: 684-93-5

Grant and Affiliation Information for Chemoprevention of rat prostate carcinogenesis by soy isoflavones and by Bowman-Birk inhibitor.

AFFILIATION: Life Sciences Group, IIT Research Institute, Chicago, Illinois 60616, USA. dmccormick@iitri.org

Country: United States

AGENCY: United States NCI

GRANT: N01-CN-85177

ACRONYM: CN

MEDLINETA: Nutr Cancer

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Chemoprevention of rat prostate carcinogenesis by soy isoflavones and by Bowman-Birk inhibitor Related Publications

• Abundant L-type calcium channel Ca(v)1.3 (alpha1D) subunit mRNA is detected in rod photoreceptors of the mouse retina via in situ hybridization.
• Acute and chronic mesenteric ischemia.
• Angioendothelioma of hypopharynx.
• Chemoprevention of rat prostate carcinogenesis by soy isoflavones and by Bowman-Birk inhibitor.
• Children's self-reported coping strategies: the role of defensiveness and repressive adaptation.
• Choice of sulfonamide drugs for local use.
• Commentary.
• Comparing the effectiveness of vision screenings as part of the school entrance physical examination to comprehensive vision examinations in children ages 3 to 6: an exploratory study.
• Determinants of seed removal distance by scatter-hoarding rodents in deciduous forests.
• Development of a shape memory alloy actuator for transanal endoscopic microsurgery.
• Does deep water running reduce exercise-induced breast discomfort?
• Features of the mammalian orthoreovirus 3 Dearing l1 single-stranded RNA that direct packaging and serotype restriction.
• Genotypic and phenotypic characterization of Lactobacillus casei strains isolated from different ecological niches suggests frequent recombination and niche specificity.
• HEPES-stabilized encapsulation of Salmonella typhimurium.
• Human Group C rotaviruses identified in Nigerian children.
• Intracochlear pressure and derived quantities from a three-dimensional model.
• Ischemic colitis complicating major vascular surgery.
• Isolation and characterization of tetracycline-resistant Citrobacter spp. from catfish.
• Meconic Acid and Alkaloids in Papaver somniferum and P. bracteatum.
• Null effect of dietary restriction on prostate carcinogenesis in the Wistar-Unilever rat.
• Patient choice at the end of life: getting the language right.
• Predictors of practitioner self-reported use of evidence-based practices: practitioner training, clinical setting, and attitudes toward research.
• Rash and desquamating skin in a neonate.
• Rotavirus immunisation in Africa: a perspective.
• The discordant eardrum.
• Total internal reflection with fluorescence correlation spectroscopy.
• Toxic reactions to streptomycin in patients with pulmonary tuberculosis having thoracic surgery.
• Use of nitrofuran therapy in external otitis.
• Vapor-liquid equilibrium of ethanol by molecular dynamics simulation and Voronoi tessellation.
• Would you like some cardiopulmonary bypass with your coronary revascularization?